Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: GDRX stock price vs ADI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ADI's multiple
Needs ADI P/E.
Implied fair value · at GDRX's multiple
Needs GDRX P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GDRX FY 2025 (ended Dec 31, 2025) · ADI FY 2025 (ended Nov 1, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
GoodRx Holdings, Inc. · implied price per share
Bear
$2.87
Base
$3.38
Bull
$3.88
Analog Devices, Inc. · implied price per share
Bear
$67.05
Base
$78.89
Bull
$90.72
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.81x
0.25x
Net debt / EBITDA
Leverage against operating earnings
1.26x
0.99x
Cash and equivalents
Liquid reserves on the balance sheet
$261.82M
$3.65B
Total debt
Interest-bearing obligations outstanding
$500.00M
$8.59B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Evolent Health, Inc.
GDRX vs EVH
CVS HEALTH Corp
GDRX vs CVS
Doximity, Inc.
GDRX vs DOCS
Criteo S.A.
GDRX vs CRTO
Texas Instruments Incorporated
GDRX vs TXN
Intel Corporation
GDRX vs INTC
NVIDIA Corporation
GDRX vs NVDA
Qualcomm Incorporated
GDRX vs QCOM
Broadcom Inc.
GDRX vs AVGO
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe GDRX can improve growth and margins while maintaining balance sheet stability, then the stock can be attractive because it trades well below ADI-implied P/E valuation and below ADI on most trading multiples; otherwise, the weak Z-Score and thin profitability argue for caution.
GDRX trades at $3.05 versus a P/E implied price of $7.44, suggesting meaningful upside on that basis, but the stock also sits within a much lower DCF range of $3.44 to $4.65 and near the historical band of $2.75 to $3.35. The gap is driven by a much lower absolute valuation profile than ADI, but the comparison is complicated because ADI is materially stronger on growth and margins.
Supporting Metrics
